Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03180294 · OUTCOME

Perception of Risk vs. Benefit at 9 Weeks

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer · Source last updated 2026-07-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
9 weeks from start of study treatment (within 21 days of randomization)

What was measured

Participants are asked, "Were the benefits of this treatment greater than any side effects?"

Analysis population: Eligible with data

Groups in this outcome

Bupropion 150 mg

One Bupropion 150 mg XL capsule PO in a.m. daily for one week; one Bupropion 150 mg XL capsule and one placebo capsule PO in a.m. daily for 8 weeks; one placebo capsule daily PO in a.m. for one 1 week (titration off).

Bupropion 300 mg

One Bupropion 150 mg XL capsule PO in a.m. daily for one week; two Bupropion 150 mg XL capsules PO in a.m. daily for 8 weeks (300 mg target dose); one Bupropion 150 mg XL capsule PO in a.m. daily for 1 week (titration off)

Placebo

One placebo capsule PO in a.m. daily for 1 week; two placebo capsules PO in a.m. daily for 8 weeks; one placebo capsule PO in a.m. daily for 1 week (titration off)

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Bupropion 150 mg67
Bupropion 300 mg58
Placebo61

Reported measurements

No
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Bupropion 150 mg37Not reportedNot reportedNot reportedNot reported
Bupropion 300 mg32Not reportedNot reportedNot reportedNot reported
Placebo40Not reportedNot reportedNot reportedNot reported
Yes
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Bupropion 150 mg30Not reportedNot reportedNot reportedNot reported
Bupropion 300 mg26Not reportedNot reportedNot reportedNot reported
Placebo21Not reportedNot reportedNot reportedNot reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. group Ids
    1. OG000
    2. OG002
    non Inferiority Type
    SUPERIORITY
    p Value
    0.23
    p Value Comment
    One-sided significance level 0.05
    statistical Method
    t-test, 1 sided
  2. group Ids
    1. OG001
    2. OG002
    non Inferiority Type
    SUPERIORITY
    p Value
    0.25
    p Value Comment
    One-sided significance level 0.05
    statistical Method
    t-test, 1 sided
Complete source fields
analyses
  1. group Ids
    1. OG000
    2. OG002
    non Inferiority Type
    SUPERIORITY
    p Value
    0.23
    p Value Comment
    One-sided significance level 0.05
    statistical Method
    t-test, 1 sided
  2. group Ids
    1. OG001
    2. OG002
    non Inferiority Type
    SUPERIORITY
    p Value
    0.25
    p Value Comment
    One-sided significance level 0.05
    statistical Method
    t-test, 1 sided
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        37
      2. group Id
        OG001
        value
        32
      3. group Id
        OG002
        value
        40
    title
    No
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        30
      2. group Id
        OG001
        value
        26
      3. group Id
        OG002
        value
        21
    title
    Yes
denoms
  1. counts
    1. group Id
      OG000
      value
      67
    2. group Id
      OG001
      value
      58
    3. group Id
      OG002
      value
      61
    units
    Participants
description
Participants are asked, "Were the benefits of this treatment greater than any side effects?"
groups
  1. description
    One Bupropion 150 mg XL capsule PO in a.m. daily for one week; one Bupropion 150 mg XL capsule and one placebo capsule PO in a.m. daily for 8 weeks; one placebo capsule daily PO in a.m. for one 1 week (titration off).
    id
    OG000
    title
    Bupropion 150 mg
  2. description
    One Bupropion 150 mg XL capsule PO in a.m. daily for one week; two Bupropion 150 mg XL capsules PO in a.m. daily for 8 weeks (300 mg target dose); one Bupropion 150 mg XL capsule PO in a.m. daily for 1 week (titration off)
    id
    OG001
    title
    Bupropion 300 mg
  3. description
    One placebo capsule PO in a.m. daily for 1 week; two placebo capsules PO in a.m. daily for 8 weeks; one placebo capsule PO in a.m. daily for 1 week (titration off)
    id
    OG002
    title
    Placebo
param Type
COUNT_OF_PARTICIPANTS
population Description
Eligible with data
reporting Status
POSTED
time Frame
9 weeks from start of study treatment (within 21 days of randomization)
title
Perception of Risk vs. Benefit at 9 Weeks
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice